Centessa Pharmaceuticals plc American Depositary Shares (CNTA)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with business quality. Centessa is a 129-employee neuroscience biotech developing orexin-based therapeutics. Its lead asset, ORX750, is in Phase IIa for central disorders of hypersomnolence, including narcolepsy types 1 and 2 and idiopathic hypersomnia; ORX142 is in Phase I. That is promising science, but not yet a proven business. In the first quarter of 2025, Centessa reported $15.0 million of revenue and a net loss of $26.1 million, for a -174.23% margin. For the trailing twelve months, the data show free cash flow of -$209.2 million and a FairStock-calculated FCF yield of -3.4%. FairStock's Piotroski score is 1/9, and its FairStock Score is 38/100, both weak signals. The balance sheet looks less leveraged, with D/E of 0.24 and an Altman Z-Score of 21.41, but cash burn is the real issue. Valuation is demanding. At the 2026-06-29 close of $40.50, the market cap is $6.1 billion. FairStock calculations show P/B of 12.86, ROE of -57.38%, and ROCE of -27.43%. The P/E is negative at -22.75 because there are no profits. The shares sit near the top of a 52-week range of $17.05-$40.56. The Lynch category is none because there are only 0 years of filed results, and three are needed. Growth data are absent, while profit growth is -203.20%. A biotech can re-rate on clinical data, but I see little margin of safety unless ORX750 and ORX142 prove themselves.

In plain English: Centessa is a small biotech working on brain-related medicines, mainly for sleepiness disorders such as narcolepsy. It is not yet profitable: in the first quarter of 2025 it had $15.0 million of revenue but lost $26.1 million. The stock looks expensive on its current numbers because the business has no steady profits and trades at a high price compared with its accounting value, though it is near the top of its 52-week range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-06-29 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer